Physician profile
Anne Chapas
NPI 1467417360
$222,717.51
in general payments reported to CMS, 2019-2025
23 companies · $35K in 2025
The $35K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $28K · 2021: $31K · 2022: $44K · 2023: $34K · 2024: $13K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $42K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Food and Beverage: $2,782 · Travel and Lodging: $1,946 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $42,447.56 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,550.00 |
| Food and Beverage | $2,781.65 |
| Travel and Lodging | $1,946.19 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solta Medical, A Division of Bausch Health US, LLC | $105,377.92 | 2019-2025 | |
| Allergan, INC. | $44,515.56 | 2019-2022 | |
| Abbvie INC. | $33,978.79 | 2023-2025 | Botox, Kybella |
| Galderma Laboratories, L.P. | $24,402.51 | 2019-2025 | |
| Merz North America, INC. | $5,052.94 | 2019-2023 | Xeomin |
| Sun Pharmaceutical Industries INC. | $4,902.00 | 2019 | |
| Lumenis Be LTD | $1,800.00 | 2025 | M22 |
| Botanix Sb INC | $1,091.01 | 2025 | Sofdra |
| Almirall LLC | $800.00 | 2021 | |
| Avita Medical Americas, LLC | $220.55 | 2022 | |
| Endo Pharmaceuticals INC. | $114.41 | 2019 | |
| Revance Therapeutics, INC. | $103.96 | 2024 | Daxxify |
| Leo Pharma INC. | $88.89 | 2019-2025 | Anzupgo |
| Dermira, INC. | $70.31 | 2019 | |
| Arcutis Biotherapeutics, INC. | $46.20 | 2025 | Zoryve |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $32.19 | 2019-2020 | |
| Biofrontera INC. | $26.43 | 2019 | |
| Incyte Corporation | $26.29 | 2024 | Opzelura |
| Dusa Pharmaceuticals, INC. | $20.29 | 2019 | |
| Aclaris Therapeutics, INC. | $18.34 | 2019 | |
| Journey Medical Corporation | $17.67 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $11.25 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Chapas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.